(Timings are in Greenwich Mean Time - add session to your diary using link below)
TriCAM - Results of a pilot RCT on CAM during allogeneic stem cell transplantation
Introduction: Allogeneic Stem Cell Transplantation (aSCT) is the only curative therapy for many hematological malignancies such as leukemia. Patients undergoing aSCT have a 30-70% chance of developing acute Graft versus Host disease (aGvHD), often with severe and lasting physical and emotional impairments leading to depression and poor quality of life (QoL), despite extensive research for preventive strategies. In this pilot study,the effects of an integrative approach on QoL and on the adverse effects during the course of aSCT were investigated.